Literature DB >> 24615173

Production and assessment of ovine antisera for the manufacture of a veterinary adder antivenom.

F M S Bolton1, N R Casewell, I Al-Abdulla, J Landon.   

Abstract

Medically important venomous snakes in Western Europe are Vipera ammodytes, Vipera aspis, Vipera berus and Vipera latastei. Envenomation of dogs and other animals by these snakes receives limited attention despite the relative frequency and potential mortality and morbidity. This reflects, in part, the lack of a dedicated veterinary antivenom. Successful antivenoms are derived from antisera containing high levels of specific polyclonal antibodies that bind to, and neutralise, all the toxins present. This requires a careful choice of immunogen, animals and immunisation schedule. We detected proteomic variation in the venoms of V ammodytes, V aspis, V berus and V latastei by SDS-PAGE (sodium dodecyl sulphate-polyacrylamide gel electrophoresis) gel electrophoresis. Consequently, we used a mixture containing equal amounts of venom from these species to immunise a flock of sheep. We demonstrate that immunisation resulted in antisera containing high levels of specific antibodies directed against the majority of toxic components found in all four snake venoms using immunoblotting, ELISA and small-scale affinity chromatography assays. The latter shows that all 25 sheep responded quickly and maintained high levels of specific antibodies throughout the two-year period of study. This ensures a consistent starting material for the manufacture of a reproducible veterinary antivenom, ViperaVet. Our next objectives are to purify the antibodies from our antisera and demonstrate their preclinical neutralising efficacy in murine animal studies prior to undertaking a clinical trial in envenomed patients.

Entities:  

Keywords:  Dogs; Immunology; Poisoning; Serology; Toxicology

Mesh:

Substances:

Year:  2014        PMID: 24615173     DOI: 10.1136/vr.102286

Source DB:  PubMed          Journal:  Vet Rec        ISSN: 0042-4900            Impact factor:   2.695


  5 in total

1.  Immunological cross-reactivity and neutralisation of European viper venoms with the monospecific Vipera berus antivenom ViperaTAb.

Authors:  Nicholas R Casewell; Ibrahim Al-Abdulla; David Smith; Ruth Coxon; John Landon
Journal:  Toxins (Basel)       Date:  2014-08-19       Impact factor: 4.546

2.  Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection.

Authors:  Stuart David Dowall; Jo Callan; Antra Zeltina; Ibrahim Al-Abdulla; Thomas Strecker; Sarah K Fehling; Verena Krähling; Andrew Bosworth; Emma Rayner; Irene Taylor; Sue Charlton; John Landon; Ian Cameron; Roger Hewson; Abdulsalami Nasidi; Thomas A Bowden; Miles W Carroll
Journal:  J Infect Dis       Date:  2015-12-28       Impact factor: 5.226

3.  Preclinical Assessment of a New Polyvalent Antivenom (Inoserp Europe) against Several Species of the Subfamily Viperinae.

Authors:  Alejandro García-Arredondo; Michel Martínez; Arlene Calderón; Asunción Saldívar; Raúl Soria
Journal:  Toxins (Basel)       Date:  2019-03-05       Impact factor: 4.546

4.  The development and evaluation of the efficacy of ovine-derived experimental antivenom immunoserum against Macrovipera lebetina obtusa (MLO) venom.

Authors:  Arsen Kishmiryan; Gevorg Ghukasyan; Lusine Ghulikyan; Anna Darbinyan; Lilia Parseghyan; Armen Voskanyan; Naira M Ayvazyan
Journal:  J Venom Res       Date:  2021-02-17

5.  Persistent hypercoagulability in dogs envenomated by the European adder (Vipera berus berus).

Authors:  Hannah J Harjen; Marit Hellum; Runa Rørtveit; Malin Oscarson; Kristin P Anfinsen; Elena R Moldal; Susanna Solbak; Sandip M Kanse; Carola E Henriksson
Journal:  PLoS One       Date:  2022-02-18       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.